In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy.
Vulnerabilities or disruptions to the global medicine supply chain (including drug shortages) continue to make headlines.
Standards play an important role in the global medicines supply chain, helping governments and manufacturers increase the availability of safe, quality medicines, as well as building patient and health provider trust. In fact, quality standards are a big reason why we in the U.S. can get a prescription filled at our neighborhood pharmacy and trust that the medicine we receive will be safe and work as it should.
Patient access to cancer drugs can mean the difference between life and death. Persistent shortages threaten patients’ access to the lifesaving and life-sustaining therapies they need.
Advanced manufacturing technologies like pharmaceutical continuous manufacturing (PCM) can provide potential efficiencies for many medicines and their ingredients, thereby facilitating geographic diversity in manufacturing and supply chain resilience. One of the ways the U.S.
A recently completed pilot project in Vietnam to validate and implement monitoring procedures for nitrosamine impurities in medicines is an inspiring example of how international collaboration and cooperation can help ensure medicines quality across geographies and strengthen the supply chain.
USP’s supplier qualification standard became official on Aug.